Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620629 | 0.99 | MAPT (0.58) | MAPTESR2NR1H2MAPK1GPR119 | |
| SCHEMBL30805657 | 0.99 | MAPT (0.58) | MAPTESR2NR1H2MAPK1GPR119 | |
| SCHEMBL7669805 | 0.97 | MAPT (0.57) | MAPTESR2NR1H2MAPK1GPR119 | |
| SCHEMBL11929920 | 0.88 | ESR2 (0.51) | MAPTESR2NR1H2MAPK1GPR119 | |
| SCHEMBL29710237 | 0.87 | MAPT (0.47) | MAPTESR2NR1H2MAPK1GPR119 | |
| SCHEMBL8228976 | 0.87 | MAPT (0.47) | MAPTESR2NR1H2MAPK1GPR119 | |
| SCHEMBL25153126 | 0.80 | MAPT (0.55) | MAPTESR2NR1H2MAPK1GPR119 | |
| SCHEMBL13226239 | 0.80 | ESR2 (0.63) | MAPTESR2NR1H2MAPK1GPR119 | |
| SCHEMBL4869824 | 0.80 | MAPT (0.67) | MAPTESR2NR1H2MAPK1DDB1 | |
| SCHEMBL30370414 | 0.80 | MAPT (0.55) | MAPTESR2NR1H2MAPK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | MAPT 2957/4885ESR2 917/4885NR1H2 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.